New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban wi
Go back to New Data from U.S. Post-Approval Study Assess Ischemic Stroke and Intracranial Hemorrhage Rates in People with Non-Valvular Atrial Fibrillation Comparing Both Rivaroxaban with Warfarin and Apixaban wi| Johnson & Johnson (NYSE: JNJ) | Delayed: 269.12 -6.11 (2.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $275.23 | 52 Week High | $126.07 | |||
| Open | $271.28 | 52 Week Low | $94.28 | |||
| Day High | $271.99 | P/E | 55.95 | |||
| Day Low | $266.88 | EPS | $4.81 | |||
| Volume | 7,768,041 | |||||
